Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints
Kidney Int Rep
.
2020 May 23;5(8):1302-1305.
doi: 10.1016/j.ekir.2020.05.011.
eCollection 2020 Aug.
Authors
Salem Almaani
1
,
Udayan Bhatt
1
,
Cristina Arriens
2
3
,
Eloisa Bonfa
4
,
Maria Dall'Era
5
,
Frederic Houssiau
6
,
Kenneth Kalunian
7
,
Megan Mackay
8
,
Jorge Sanchez-Guerrero
9
,
Neil Solomons
10
,
Brad H Rovin
1
Affiliations
1
Division of Nephrology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
2
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
3
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
4
Hospital das Clinicas da Universidade de Sao Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
5
Division of Rheumatology, University of California, San Francisco, California, USA.
6
Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium.
7
Department of Medicine, University of California at San Diego, La Jolla, California, USA.
8
Feinstein Institute for Medical Research, Manhasset, New York, USA.
9
Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada.
10
Aurinia Pharmaceuticals Inc., Victoria, British Columbia, Canada.
PMID:
32775830
PMCID:
PMC7403554
DOI:
10.1016/j.ekir.2020.05.011
No abstract available